GENinCode Press Releases

Published on December 4, 2025 - 11:01 GMT

CARDIO inCode-Score® collaboration with Thermo Fisher Scientific

Commercialisation agreement to sell, distribute and manufacture CARDIO inCode-Score® for the genetic risk prediction and prevention of coronary heart disease OXFORD, UNITED KINGDOM, December 4, 2025 /⁨EINPresswire.com⁩/ -- GENinCode Plc (AIM: GENI), the Oxford based predictive genetics company focused on the prevention of cardiovascular disease (“CVD”) and risk assessment of ovarian cancer, announces today a collaboration with Thermo Fisher Scientific to sell, distribute and manufacture the CARDIO inCode- …

Distribution channels: Banking, Finance & Investment Industry, Companies ...
Published on December 4, 2025 - 10:20 GMT

CARDIO inCode-Score® collaboration with Thermo Fisher Scientific

Commercialisation agreement to sell, distribute and manufacture CARDIO inCode-Score® for the genetic risk prediction and prevention of coronary heart disease OXFORD, UNITED KINGDOM, December 4, 2025 /⁨EINPresswire.com⁩/ -- GENinCode Plc (AIM: GENI), the Oxford based predictive genetics company focused on the prevention of cardiovascular disease (“CVD”) and risk assessment of ovarian cancer, announces today a collaboration with Thermo Fisher Scientific to sell, distribute and manufacture the CARDIO inCode- …

Distribution channels: Banking, Finance & Investment Industry, Companies ...
Published on December 3, 2025 - 14:52 GMT

New York State clinical test approval of CARDIO inCode-Score®

IRVINE, CA, UNITED STATES, December 3, 2025 /⁨EINPresswire.com⁩/ -- GENinCode US Inc the Irvine based predictive genetics company focused on the prevention of coronary heart disease (“CHD” or “Heart Disease”) and risk assessment of ovarian cancer, announces today the test approval by the New York State Department of Health, Clinical laboratory Evaluation Program, of CARDIO inCode-Score® Polygenic Risk Score (“PRS”) for the prediction and prevention of coronary heart disease. The approval of CARDIO inCode …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
Published on December 16, 2024 - 13:00 GMT

CARDIO inCode® publication in International Journal of Cardiology Cardiovascular Risk and Prevention

Individuals with a high polygenic risk are likely to derive the most benefit from lifestyle change and/or therapeutic intervention IRVINE, CA, UNITED STATES, December 16, 2024 /⁨EINPresswire.com⁩/ -- GENinCode U.S., the genetics company focused on the prevention of cardiovascular disease, announces the publication in the International Journal of Cardiology Cardiovascular Risk and Prevention of a clinical research study on the ‘Interplay between Lifestyle Factors and Polygenic Risk for Incident Coronary …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
Published on September 20, 2024 - 12:45 GMT

DISCOVER FH collaboration with Family Heart Foundation®, UT Southwestern, and Partners

LIPID inCode®, tests patients to identify familial hypercholesterolemia and prevent cardiovascular disease OXFORD, UNITED KINGDOM, September 20, 2024 /⁨EINPresswire.com⁩/ -- GENinCode Plc (LSE AIM: GENI), the genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces its collaboration with The Family Heart Foundation®, UT Southwestern, and other partner members to use the LIPID inCode® monogenic and polygenic test in US Primary and Secondary Care settings for the …

Distribution channels: Banking, Finance & Investment Industry, Companies ...
Published on August 29, 2024 - 10:00 GMT

CARDIO inCode-Score presentation on polygenic risk of Coronary Heart Disease at the 2024 ESC Annual Congress, London

IRVINE, US, August 29, 2024 /⁨EINPresswire.com⁩/ -- GENinCode US Inc, the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces the presentation by Kaiser Permanente on the interplay between family history and polygenic risk on the incidence of coronary heart disease (“CHD”) which will take place at the 2024 Annual Congress of the European Society of Cardiology (“ESC”) in London from 30 August to 2 September 2024. Following the March 2024 milestone …

Distribution channels: Banking, Finance & Investment Industry, Companies ...

Contact

Matthew Walls
GENinCode
+44 7887 501998

email us here

Share This Newsroom

Facebook Twitter LinkedIn

Company/Organization

GENinCode PLC
One St Peters Square
Manchester, M2 3DE
United Kingdom
+44 7887 501998
Visit Website

Facebook X LinkedIn

About

GENinCode provide patients and physicians with globally leading risk assessment tools to inform cardiovascular preventive care and treatment. Our technologies combine monogenic, polygenic and clinical information to provide advanced patient risk assessment to predict and prevent cardiovascular disease.

http://www.genincode.com

The Newsroom of GENinCode PLC

CARDIO inCode-Score® collaboration with Thermo Fisher Scientific

CARDIO inCode-Score® collaboration with Thermo Fisher Scientific

New York State clinical test approval of CARDIO inCode-Score®

CARDIO inCode® publication in International Journal of Cardiology Cardiovascular Risk and Prevention

DISCOVER FH collaboration with Family Heart Foundation®, UT Southwestern, and Partners

CARDIO inCode-Score presentation on polygenic risk of Coronary Heart Disease at the 2024 ESC Annual Congress, London